IMPDH1 is a potential immune evasion-related oncoprotein in endometrial cancer Authors: Yongning Chen, Fei Ma, Weichang Chen, Ruibin Jiang, Fei Wu, Shipeng Gong, Yadi Zhang Published: 2026 ABSTRACT AbstractEndometrial cancer is one of the most common gynecologic malignancies, with increasing evidence suggesting the involvement of immune-related processes rather than direct immune evasion mechanisms in its progression. However, effective immune-related biomarkers for prognostic evaluation and therapeutic targeting remain limited. This study aimed to identify novel immune-associated molecules based on clinical endometrial cancer specimens using integrated proteomic and bioinformatic approaches. Proteomic analysis was performed on tumor and adjacent normal tissues from endometrial cancer patients. Differentially expressed proteins were screened and further analyzed through transcriptomic validation, survival analysis, immune infiltration assessment, and pathway enrichment to explore their clinical relevance and potential functional roles in the tumor immune microenvironment. IMPDH1 was identified as a significantly upregulated protein in endometrial cancer and was associated with unfavorable prognosis. High expression of IMPDH1 was correlated with reduced CD8⁺ T cell infiltration and features of an immunosuppressive tumor microenvironment. Functional enrichment suggested its involvement in purine metabolism and a potential role in immune-related processes. This study identifies IMPDH1 as a novel immune-related biomarker in endometrial cancer, with potential value for prognosis and immunotherapy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12863-026-01427-5.Keywords: Endometrial cancer, IMPDH1, Immune evasion, CD8⁺ T cells, Proteomics Introduction Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, and its incidence continues to rise globally, particularly in younger and obese populations [1]. While most early-stage EC cases are effectively managed by surgery and adjuvant therapies, with a five-year survival rate of approximately 95% for localized disease, the prognosis of advanced, recurrent, or high-grade tumors remains poor due to limited treatment efficacy and high rates of relapse, with five-year survival dropping to around 16–18% for distant-stage disease [2]. Despite recent advances in molecular classification, the therapeutic landscape for EC has not significantly changed for decades – standard treatments have remained largely unchanged – highlighting the urgent need for novel biomarkers and therapeutic targets to improve clinical outcomes [3]. In recent years, immunotherapy has shown promise in a subset of endometrial cancer patients, particularly those with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, which tend to respond better to immune checkpoint blockade [3]. However, the overall response rate remains modest, and primary or acquired resistance to immune checkpoint inhibitors continues to pose a major clinical challenge. For example, only approximately half of patients with mismatch repair-deficient endometrial cancer derive significant clinical benefit from Programmed cell death protein 1 (PD-1) or Programmed death-ligand 1 (PD-L1) blockade [4]. A growing body of evidence suggests that tumor immune evasion plays a central role in limiting the efficacy of immunotherapy, yet the molecular regulators that mediate this process in EC are incompletely understood [5]. Inosine-5′-monophosphate dehydrogenase type I (IMPDH1) is a key enzyme in the de novo guanine nucleotide biosynthesis pathway, essential for generating guanosine triphosphate (GTP) needed for DNA replication and cell proliferation [6]. Emerging studies have demonstrated that IMPDH1 is overexpressed in multiple human cancers and may promote tumor growth, drug resistance, and immune modulation. For instance, pan-cancer analyses report that high IMPDH1 expression is associated with poor prognosis in several tumor types and is closely linked to immune-related pathways and processes such as cytokine signaling and T-cell regulatory pathways [7]. Moreover, IMPDH1 expression has been correlated with an immunosuppressive tumor microenvironment – for example, high IMPDH1 levels tend to be associated with reduced infiltration of CD8⁺ T cells and with elevated expression of inhibitory immune checkpoints such as PD-1, Cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) [7], suggesting a potential role in immune escape mechanisms. Additional studies have reinforced the oncogenic role of IMPDH1 by showing that its loss inhibits tumor initiation and growth in hepatocellular carcinoma, highlighting its essential function in tumorigenesis. These findings collectively underscore the importance of IMPDH1 in both tumor progression and immune modulation [8]. Although proteomic studies in endometrial cancer have revealed dysregulated immune, cell death, and signaling pathways in early-stage tumors, the functional roles of specific immune-modulatory proteins, particularly IMPDH1 in tumor immune evasion, remain unclear [9]. In this study, we identified elevated IMPDH1 expression in endometrial cancer by proteomic profiling and integrative transcriptomic and immunogenomic analyses, found that it is associated with immune infiltration, checkpoint expression, and potential immunotherapy response, suggesting that IMPDH1 may be involved in immune evasion–related processes and may represent a candidate biomarker and therapeutic target. Methods Sample collection This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (NFEC-2016-110). Written informed consent was obtained from all patients prior to sample collection. A total of 18 surgical specimens were collected at Nanfang Hospital between 2017 and 2019, including 8 endometrial carcinoma tissues and 10 normal endometrial tissues. Normal endometrial tissues were obtained from patients undergoing surgery for benign gynecological conditions. These samples were used for subsequent proteomic analysis. Proteomics sample preparation, data acquisition, and analysis Tissue protein extraction and enzymatic digestion were performed using a pressure cycling technology (PCT)-based protocol, following previously published methods [10]. Data-independent acquisition (DIA) mass spectrometry was conducted using a DIONEX UltiMate 3000 RSLCnano system coupled with a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). Briefly, peptides dissolved in 0.1% formic acid were separated at a nano-flow rate (~ 300 nL/min) using a multistep gradient elution (buffer A: 0.1% formic acid in water; buffer B: 0.1% formic acid in acetonitrile) over approximately 120 min, followed by a high-organic wash to remove retained peptides. Peptides were ionized at ~ 1.8–2.0 kV and analyzed in DIA mode on the Orbitrap platform. Full MS scans were acquired over a mass range of 350–1250 m/z, followed by DIA MS/MS scans with multiple isolation windows covering the major precursor ion range. DIA data were analyzed in a library-free mode using DIA-NN (version 1.8.1) against the human reference proteome database (UniProt, Homo sapiens). Key parameters included trypsin specificity with up to two missed cleavages, carbamidomethylation (C) as a fixed modification, oxidation (M) as a variable modification, and a false discovery rate (FDR) of 1% at both precursor and protein levels. Protein intensities were normalized using the internal normalization algorithm implemented in DIA-NN. No additional batch correction was applied, as normalization effectively minimized technical variation across samples. Protein quantification was performed using the integrated DIA-NN algorithm, and log2-transformed protein intensity values were used for downstream analysis. The resulting protein intensity matrix was filtered to retain proteins with at least two valid values in any one group. Missing values were imputed using a normal distribution based on the total data matrix. For differential expression analysis, unpaired Student’s t-test was applied to log2-transformed intensity values. Proteomic data analysis Raw data from proteomic profiling were processed to identify differentially expressed proteins between endometrial cancer and normal endometrial tissues. Statistical analysis was conducted using the Limma package in R (version 4.2.0). Proteins with an adjusted p-value < 0.05 and |log₂ fold change| > 1 were considered significantly differentially expressed. Multiple testing correction was performed using the Benjamini–Hochberg method. Visualization of the results was performed in R using the packages ggplot2 for volcano plots, FactoMineR and ggplot2 for principal component analysis (PCA), and pheatmap for heatmaps. Pan-cancer and tumor-related bioinformatic analysis The expression pattern and clinical relevance of target genes in multiple cancer types were analyzed using public databases including University of Alabama Cancer Data Analysis Portal (UALCAN), The Human Protein Atlas, and Kaplan-Meier Plotter, as well as proteomic data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Default parameters were used for all database analyses unless otherwise specified. These platforms were used to assess mRNA and protein levels, pathological subtypes, and prognostic implications across cancers. Immune-related bioinformatic analysis The immune-related functions and prognostic significance of candidate genes were explored using Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) for protein-protein interaction networks, Tumor Immune Estimation Resource (TIMER) 3.0 for immune infiltration analysis, and Kaplan-Meier Plotter for survival analysis based on immune subtypes. Correlation analyses were performed using Spearman’s method as implemented in the respective platforms. Gene set enrichment analysis (GSEA) GSEA was performed using the clusterProfiler package in R. UCEC samples were divided into high- and low-IMPDH1 expression groups according to the median expression value of IMPDH1. Genes were ranked by the difference in mean expression between the two groups, and enrichment analysis was conducted using the Hallmark gene sets from MSigDB obtained via the msigdbr package. A nominal p-value cutoff of 0.25 with 100 permutations was applied for GSEA computation. Significantly enriched pathways (adjusted p < 0.05) were selected for visualization and displayed using a dot plot, and representative pathways were further illustrated using enrichment plots. Results Unveiling the proteomic landscape of endometrial cancer tissues To characterize the proteomic alterations associated with endometrial cancer, we conducted a label-free quantitative proteomic analysis on 18 human endometrial tissue samples, including 8 tumor tissues from patients with EC and 10 normal endometrial tissues. A total of 5,331 proteins were identified across all samples. Among these, the 86 most significantly dysregulated proteins were selected based on fold change and statistical significance for subsequent analyses. As shown in Fig. 1a, a volcano plot revealed 62 significantly upregulated and 24 downregulated proteins in tumor tissues compared to controls. To explore the global proteomic variance, principal component analysis was performed (Fig. 1b), demonstrating a clear separation between tumor and normal samples, with principal component 1 (PC1) and principal component 2 (PC2) accounting for 17.77% and 11.98% of the total variance, respectively (R = 0.4726, P = 0.001). This distinction was further supported by unsupervised hierarchical clustering (Fig. 1c), which revealed consistent intra-group similarity and distinct inter-group segregation based on protein expression patterns. The heatmap and dot plot in Fig. 1c, along with the bar graph in Fig. 1d, highlighted the differential abundance of specific proteins. Notably, AT-hook-containing transcription factor 1 (AHCTF1), collagen triple helix repeat-containing protein 1 (CTHRC1), mitochondrial assembly of ribosomal large subunit 1 (MALSU1), IMPDH1, and stanniocalcin-2 (STC2) were consistently overexpressed in tumor tissues. Conversely, proteins such as glycine-rich proline-alanine-rich protein 1 (GPALPP1), migration and invasion enhancer 1 (MIEN1), tripartite motif-containing 23 (TRIM23), phosphatidic acid phosphatase type 2B (PPAP2B), and serine/threonine kinase 24 (STK24) were significantly more abundant in normal endometrial tissues. Proteomic profiling differentiates tumor and control endometrial tissues. (a) Volcano plot showing differentially expressed proteins. (b) PCA showing separation between tumor and control samples. (c) Heatmap and dot plot of selected protein expression. (d) Boxplots of representative differentially expressed proteins These distinct expression profiles between malignant and non-malignant samples underscore the proteomic divergence associated with endometrial carcinogenesis and offer insights into potential diagnostic biomarkers and therapeutic targets in EC. Characterizing the enrichment profile of tumor biology To further explore the biological implications of the differentially expressed proteins, functional enrichment analyses were performed. As shown in Fig. 2a, Gene Ontology (GO) analysis identified significant enrichment in pathways related to mitochondrial membranes, purine nucleotide metabolism, autophagosome assembly, and cytoplasmic translational regulation. These biological processes are frequently associated with metabolic reprogramming and stress adaptation in tumor cells. Figure 2b presents the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, which further supports these findings by highlighting the involvement of several tumor-associated pathways, including Fc gamma R-mediated phagocytosis, apoptosis, stem cell regulation, and Wnt signaling. In addition, classical oncogenic pathways such as Hypoxia-Inducible Factor 1 signaling pathway (HIF-1), Erb-B2 Receptor Tyrosine Kinase signaling pathway (ErbB), Mechanistic Target of Rapamycin signaling pathway (mTOR), and Toll-like receptor signaling were also significantly enriched, suggesting that the dysregulated proteins participate in a broad range of signaling cascades relevant to tumor progression and immune evasion. Functional enrichment of tumor-associated proteins. (a) GO enrichment of biological processes, cellular components, and molecular functions. (b) KEGG pathway enrichment analysis. (c) Chord plot showing associations between key genes and enriched GO terms. (d) Heatmap and boxplots of representative proteins To visualize the distribution of these functional categories, a chord diagram was generated (Fig. 2c), demonstrating that many of the candidate proteins are functionally pleiotropic and simultaneously involved in multiple biological processes. Notably, proteins annotated in mitochondrial and purine metabolism categories were extensively interconnected with immune-related and translational regulatory functions, underscoring the multifaceted role of metabolic pathways in shaping the tumor microenvironment. We further examined the expression levels of representative genes from the enriched pathways. As illustrated in Fig. 2d, genes involved in mitochondrial respiratory function and nucleotide biosynthesis, including NADH: Ubiquinone Oxidoreductase Subunit A3 (NDUFA3), NADH: Ubiquinone Oxidoreductase Subunit B11 (NDUFB11), Succinate Dehydrogenase Complex Subunit C (SDHC), and IMPDH1, were markedly upregulated in tumor tissues compared to controls. In contrast, Tyrosylprotein Sulfotransferase 2 (TPST2) and Fragile Histidine Triad Diadenosine Triphosphatase (FHIT), genes associated with stress response and potential tumor suppression, were significantly downregulated. These differential patterns were consistently observed across individual samples, as visualized in the clustered heatmap, and further supported by quantitative comparison through boxplot analysis. Together, these results suggest that endometrial cancer is characterized by coordinated alterations in metabolic and immune-related proteins, which may serve as potential biomarkers or therapeutic targets. Exploring the clinical and molecular implications of IMPDH1 upregulation Based on the proteomic profiling results, IMPDH1 emerged as one of the most upregulated proteins in endometrial cancer tissues. Given its putative role in purine metabolism and immune regulation, we selected IMPDH1 for further validation and functional exploration. To further investigate the clinical relevance of IMPDH1, we analyzed its expression and prognostic significance across multiple cancer types using publicly available bioinformatics datasets, with subsequent validation using CPTAC proteomic data. As shown in Fig. 3a, pan-cancer analysis demonstrated that IMPDH1 expression was significantly upregulated in multiple tumor types compared to their corresponding normal tissues, including UCEC (Uterine Corpus Endometrial Carcinoma), which was further supported by CPTAC data (Figure S1). In UCEC specifically, stratified analysis revealed that IMPDH1 expression was elevated across different histological subtypes (Fig. 3b), as well as in all tumor stages relative to normal endometrial tissues (Fig. 3c). Immunohistochemistry staining from The Human Protein Atlas further confirmed higher IMPDH1 protein levels in tumor tissues than in normal controls (Fig. 3d). Consistently, immunofluorescence staining in glioma (U-251MG) and osteosarcoma (U2OS) cell lines showed subcellular localization of IMPDH1 primarily in the cytoplasm and endoplasmic reticulum (Fig. 3e). Expression and clinical relevance of IMPDH1 in UCEC. (a) Pan-cancer expression of IMPDH1 across tumor and normal tissues (TCGA). (b) IMPDH1 expression by histological subtype. (c) IMPDH1 expression across clinical stages. (d) Immunohistochemistry (IHC) showing IMPDH1 expression in tumor and normal tissues. (e) Immunofluorescence images showing co-localization of IMPDH1 with microtubules and endoplasmic reticulum in glioma (U-251MG) and osteosarcoma (U2OS) cells. (f) Kaplan–Meier analysis of overall survival based on IMPDH1 expression. (g) Combined survival analysis of IMPDH1 expression and menopausal status To determine the prognostic significance of IMPDH1 in endometrial cancer, Kaplan–Meier survival analysis was performed. High expression of IMPDH1 was significantly associated with worse overall survival in UCEC patients (HR = 2.19, 95% CI: 1.1–4.33, log-rank p = 0.021) (Fig. 3f). Moreover, subgroup analysis revealed that the prognostic effect of IMPDH1 was particularly pronounced in postmenopausal patients, further implicating its clinical relevance in a hormone-dependent tumor context (Fig. 3g). These findings collectively suggest that IMPDH1 may function as a tumor-promoting factor and potential prognostic biomarker in endometrial cancer. Deciphering the immune landscape and prognostic value of IMPDH1 in UCEC To investigate the immunological implications of IMPDH1 in UCEC, we conducted a series of analyses focusing on protein interaction networks, immune cell infiltration, and clinical relevance. The protein-protein interaction network constructed via STRING revealed that IMPDH1 is functionally linked to enzymes involved in purine biosynthesis, such as Guanine Monophosphate Synthase (GMPS), Inosine Monophosphate Dehydrogenase 2 (IMPDH2), and Hypoxanthine Phosphoribosyltransferase 1 (HPRT1), suggesting its centrality in nucleotide metabolism pathways (Fig. 4a). Using the TIMER database, we evaluated the relationship between IMPDH1 expression and immune infiltration. A statistically significant negative correlation was observed between IMPDH1 expression and CD8⁺ T cell abundance (Rho = − 0.271, p = 0.0108), whereas no strong association was found with tumor purity (Fig. 4b), indicating that its expression may be specifically related to immune exclusion mechanisms. To further explore this association, we analyzed the impact of IMPDH1 mutations on CD8⁺ T cell subtypes. As shown in Fig. 4c and d, tumors harboring IMPDH1 mutations displayed significantly reduced infiltration of both central memory (p = 0.034) and effector memory (p = 0.0088) CD8⁺ T cells, suggesting a potential role for IMPDH1 alterations in impairing effective T cell responses. Copy number alterations (CNAs) of IMPDH1 were also found to modulate immune infiltration. Tumors with arm-level deletions or amplifications exhibited markedly decreased CD8⁺ T cell presence compared to diploid or low-level gain groups (Fig. 4e, p < 0.01), highlighting the immunomodulatory consequences of genomic instability at this locus. In addition, we further examined the association between IMPDH1 expression and other immunoregulatory cell populations. IMPDH1 expression was negatively correlated with regulatory T cells (Tregs) (Rho = −0.154, p = 8.15 × 10⁻³), whereas its correlations with macrophage infiltration, including total macrophages and M1/M2 subsets, were relatively weak and not statistically significant (Figure S2). Kaplan–Meier survival analysis revealed that patients with elevated IMPDH1 expression had significantly poorer overall survival under conditions of reduced CD8⁺ T cell infiltration (HR = 4.42, p = 0.036; Fig. 4f), suggesting a potential association between IMPDH1 expression and unfavorable prognosis in tumors with low CD8⁺ T cell infiltration. Immune landscape and prognostic relevance of IMPDH1 in UCEC. (a) Protein–protein interaction (PPI) network of IMPDH1 based on STRING. (b) Correlation between IMPDH1 expression and CD8⁺ T cell infiltration (TIMER). (c) Central memory and (d) effector memory CD8⁺ T cell subsets by IMPDH1 mutation status. (e) Association between IMPDH1 CNAs and CD8⁺ T cell infiltration. (f) Kaplan-Meier analysis of overall survival based on IMPDH1 expression and CD8⁺ T cell infiltration Collectively, these findings indicate that IMPDH1 expression is associated with reduced CD8⁺ T cell infiltration and poorer clinical outcomes, suggesting its potential relevance as a biomarker of immune status in UCEC. Revealing pathway alterations associated with IMPDH1 in UCEC To explore pathways associated with IMPDH1 expression, GSEA was performed in UCEC. The overview analysis showed that multiple cancer-related pathways were enriched in the high-IMPDH1 group (Fig. 5a). Representative enrichment plots showed significant enrichment of key metabolic pathways, including glycolysis, mTORC1 signaling, and oxidative phosphorylation (Fig. 5b–d), suggesting a link between IMPDH1 expression and metabolic reprogramming. Consistent with the observed association between IMPDH1 and reduced CD8⁺ T cell infiltration, given the potential connection between metabolic alterations and immune regulation, we next examined the association between IMPDH1 and immune checkpoint molecules. IMPDH1 expression was positively correlated with CD274 (PD-L1) expression (R = 0.32, p = 8.1 × 10⁻⁶; Fig. 5e), suggesting that IMPDH1-associated metabolic reprogramming may be linked to CD8⁺ T cell exclusion, potentially through modulation of immune regulatory pathways. IMPDH1-associated pathways and immune features in UCEC. (a) GSEA overview of enriched pathways in the high-IMPDH1 group. (b–d) Enrichment plots for glycolysis, mTORC1 signaling, and oxidative phosphorylation. (e) Correlation between IMPDH1 and CD274 expression Discussion Endometrial cancer is one of the most common gynecological malignancies, with rising incidence worldwide and limited treatment options for advanced or recurrent disease. In this study, we investigated the potential role of IMPDH1 in endometrial cancer progression, focusing on its association with immune-related features. We found that IMPDH1 expression is significantly elevated in endometrial cancer tissues compared to normal endometrium, and that higher expression is associated with reduced CD8⁺ T cell infiltration and poorer clinical outcomes. Rather than establishing a direct causal role, our findings suggest that IMPDH1 is closely associated with features linked to immune evasion. These results support a potential role for IMPDH1 as an immune evasion–associated factor, with possible relevance as a prognostic biomarker and a candidate therapeutic target in endometrial cancer. A key finding of our study is the markedly elevated expression of IMPDH1 in endometrial cancer, consistent with large-scale analyses showing its overexpression in multiple malignancies, including uterine endometrial carcinoma, relative to normal tissues [7]. Functionally, this overexpression may be associated with immune escape–related features. We observed that UCEC cases with high IMPDH1 exhibited altered immune infiltration patterns, with reduced cytotoxic T lymphocyte infiltration and increased expression of inhibitory checkpoints, consistent with a relatively “cold” immune phenotype. This pattern aligns with known mechanisms of immune evasion, such as PD-L1 upregulation by cancer or immune cells, which inhibits T-cell function and prevents immune-mediated cytolysis [11]. Likewise, prior studies in EC have reported that elevated levels of immunosuppressive factors such as Cyclooxygenase-2 (COX-2) are associated with reduced infiltration of CD8⁺ T cells [2], reinforcing the concept that metabolic or inflammatory alterations can create an immune-excluded niche. Importantly, our GSEA results (Fig. 5) support these associations at the pathway level, with enrichment of glycolysis, mTORC1 signaling, and oxidative phosphorylation, pathways known to influence anti-tumor immunity through nutrient competition, T cell exhaustion, and checkpoint regulation. Therefore, IMPDH1 may be involved in shaping an immunosuppressive microenvironment through metabolic rewiring. Our data place IMPDH1 within this framework, as its dysregulation may be linked to both tumor proliferation and immune suppression. In line with this, a recent pan-cancer immunogenomic analysis reported that IMPDH1 expression correlates with immune microenvironment features [7]. In our EC cohort, high IMPDH1 expression was associated with increased expression of T-cell inhibitory receptors, including CD274 (PD-L1), suggesting a functionally suppressed state of infiltrating lymphocytes. Our findings further support the prognostic relevance of IMPDH1 in UCEC. Patients with tumors overexpressing IMPDH1 tended to have poorer survival outcomes, consistent with reports in other cancers [7]. Although limited by sample size, this association is biologically plausible given the link between immune evasion and poor outcomes. Meta-analyses show that higher CD8⁺ T-cell infiltration is associated with better survival in endometrial cancer [12], whereas immune-deserted tumors fare worse. Consistently, UCECs with high IMPDH1 expression showed reduced Tumor-Infiltrating Lymphocyte (TIL) activity, which may be associated with disease progression. Clinically, IMPDH1 may serve as a biomarker to identify high-risk, immune-evasive tumors and inform immunomodulatory strategies. Notably, the limited efficacy of single-agent checkpoint inhibitors in EC highlights the need for stratification markers such as IMPDH1 [13]. If validated, IMPDH1 could aid risk stratification and therapy selection, and integration with PD-L1 or tumor mutational burden may further refine patient identification. Overall, these findings suggest a potential role for IMPDH1 in the immune landscape and clinical behavior of EC. IMPDH1’s role in immune evasion and tumor growth supports its potential as a therapeutic target. As a key enzyme in guanine nucleotide synthesis, it is druggable, and inhibitors like mycophenolate mofetil, already used as immunosuppressants, have shown anti-tumor potential in preclinical studies [14]. However, evidence that IMPDH1 inhibition enhances anti-tumor immunity in EC remains limited and indirect. Our findings provide a plausible therapeutic rationale rather than definitive evidence. By limiting guanine nucleotide production, IMPDH1 inhibition may affect tumor proliferation and alter tumor metabolic states [15]. Given its association with checkpoint pathways, IMPDH1 inhibition may potentially synergize with PD-1/PD-L1 blockade, although this requires direct validation. Our study highlights the role of IMPDH1 in endometrial cancer but has limitations, including the relatively small size of the proteomic cohort, retrospective design, and the correlative nature of the analyses. Importantly, our findings are primarily based on bioinformatic associations and do not establish a causal link between IMPDH1 and immune evasion. Future studies incorporating genetic manipulation, immune co-culture systems, and in vivo models are needed to determine whether IMPDH1 directly regulates CD8⁺ T cell exclusion or checkpoint activation. Moreover, although we propose therapeutic potential for targeting IMPDH1, direct evidence from drug sensitivity or immunotherapy response models in UCEC is currently lacking. Further investigation integrating pharmacological inhibition with immune profiling and treatment response evaluation will be essential. In addition, prospective cohort validation is required to confirm its prognostic value [16]. Overall, our study provides a hypothesis-generating framework linking purine metabolism, metabolic reprogramming, and immune suppression in endometrial cancer. In conclusion, IMPDH1 is associated with an immunosuppressive and metabolically active tumor phenotype, and further mechanistic and translational studies are warranted to clarify its role as a therapeutic target and biomarker in endometrial cancer. Conclusion Our study, grounded in clinical endometrial cancer specimens and guided by integrative proteomic and multi-omics analyses, identifies IMPDH1 as a potential immune-related biomarker. Its elevated expression is associated with poorer clinical outcomes and reduced CD8⁺ T cell infiltration, suggesting a potential link to immune evasion. These findings provide a basis for further investigation of IMPDH1 as a prognostic indicator and a candidate target for immunotherapy in endometrial cancer. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We gratefully acknowledge the Experimental Center of Zhejiang Cancer Hospital for their assistance with proteomic sample preparation and analysis. Author contributions Yongning Chen and Fei Ma contributed to conceptualization, project administration, and writing–original draft. Weichang Chen and Ruibin Jiang were responsible for methodology, data curation, formal analysis, visualization, and writing–original draft.Fei Wu conducted investigation and validation, provided resources, and contributed to writing–review and editing. Shipeng Gong performed software work, supervision, and data curation. Yadi Zhang was involved in data curation, project administration, and writing–review and editing. All authors reviewed the manuscript. Funding This study was supported by the Medical and Health Science Program of Zhejiang Province (Grant No. 2025HY0486). Data availability The proteomics data generated in this study have been deposited in the iProX repository (http://www.iprox.cn/) under the dataset identifier IPX0015865000. Publicly available datasets were also used for validation. All other data supporting the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (Approval No. NFEC-2016-110). All procedures were conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines. Informed consent was obtained from all participants or their legal guardians. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yongning Chen and Fei Ma contributed equally to this work. Contributor Information Shipeng Gong, Email: gsp2103@163.com. Yadi Zhang, Email: flyou@smu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The proteomics data generated in this study have been deposited in the iProX repository (http://www.iprox.cn/) under the dataset identifier IPX0015865000. Publicly available datasets were also used for validation. All other data supporting the findings of this study are available from the corresponding author upon reasonable request.